Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich, RNAi Consortium Validating Clones for Second Phase of Effort

This article has been updated from a previous version to clarify Sigma-Aldrich's role in the validation process. 
NEW YORK (GenomeWeb News) - Sigma-Aldrich said today that it is working with the RNAi Consortium to functionally validate around 160,000 previously cloned, lentiviral-based shRNA vector constructs as part the second phase of the project.
The company said that so far more than 5,000 clones have been tested in the functional validation process.
“Validated clones covering more than 700 genes are available in Sigma-Aldrich's Mission shRNA collection, a number expected to grow by 75,000 clones per year through 2011,” Sigma-Aldrich said in a statement.
The company added that the consortium intends to generate and validate 150,000 additional clones to help develop new RNAi screening approaches.
The RNAi Consortium was established by the Broad Institute in 2004. The public/private alliance of RNAi researchers is developing genome-scale sets of virally expressed shRNAs targeting mouse and human genes.
A “key goal” of the consortium is to provide at least two clones with a knockdown level of 70 percent or greater for every human and mouse gene over the next four years, the company said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more